Stuart Poulton
Corporate Officer/Principal chez KARYOPHARM THERAPEUTICS INC.
Fortune : 55 452 $ au 31/03/2024
Profil
Stuart Poulton is currently the Chief Development Officer & Executive VP at Karyopharm Therapeutics, Inc. Prior to his current position, he worked as the Executive Director-Global Program Management at Amgen, Inc. from 2013 to 2016.
He also held the position of Head-Clinical Operations at Eli Lilly & Co. Additionally, Mr. Poulton served as the Vice President-Clinical Development Operations at AbbVie, Inc. from 2019 to 2022.
He completed his graduate degree at The University of New South Wales and his undergraduate degree at The University of Sydney.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/03/2024 | 36 723 ( 0,03% ) | 55 452 $ | 31/03/2024 |
Postes actifs de Stuart Poulton
| Sociétés | Poste | Début |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Corporate Officer/Principal | 01/02/2022 |
Anciens postes connus de Stuart Poulton
| Sociétés | Poste | Fin |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01/01/2022 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2016 |
| ELI LILLY AND COMPANY | Chief Tech/Sci/R&D Officer | - |
Formation de Stuart Poulton
| The University of New South Wales | Graduate Degree |
| The University of Sydney | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ABBVIE INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
